MPLT

MapLight Therapeutics, Inc.
CAPPED RATING

MapLight Therapeutics, Inc. (MPLT) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (D).

Quantitative Factor Evaluation • Updated

Overall Rating
2.0 / 5.0
C-
Value
C+
Factor Score 2.5 / 5.0
Growth
C
Factor Score 2.3 / 5.0
Profitability
D+
Factor Score 1.6 / 5.0
Momentum
D
Factor Score 1.2 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -2.1
EV / EBITDA -0.1
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -39.8%
Price Return 12M -53.1%
Catalyst Signal 0.00
Market Cap $392.9M
TTM Revenue N/A
Price / Sales N/A
ROE -111.5%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 C+ (2.5) C (2.3) D+ (1.6) D (1.2) C+ (2.6) C- (2.0)
2026-11-06 A- (3.9) C (2.2) D+ (1.7) D- (1.1) F (0.0) D+ (1.8)
2026-10-30 C+ (2.5) C (2.2) D+ (1.7) D- (1.1) F (0.0) D+ (1.5)
2026-10-23 C+ (2.5) C (2.3) D+ (1.7) D- (0.7) F (0.0) D (1.4)
2026-10-16 C+ (2.5) C (2.3) D+ (1.7) D- (0.7) F (0.0) D (1.4)
Page 1 of 4